SNSatheesh Kumar Nukala

Satheesh Kumar Nukala

*This is an algorithmically generated author record based on publicly available information.

Satheesh Kumar Nukala has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Ashok Kumar Bapuram

    Department of Chemistry, Guru Nanak Institutions Technical Campus (GNITC B-Tech-I), Ibrahimpatnam, Ranga Reddy, Hyderabad-501506 India

    3 shared publications
  • Karthik Bokkala

    Department of Chemistry Chaitanya (Deemed to be University), Kishanpura, Hanumakonda Telangana India

    2 shared publications
  • Narasimha Swamy Thirukovela

    Department of Chemistry Chaitanya (Deemed to be University), Kishanpura, Hanumakonda Telangana India

    2 shared publications
  • Narsimha Sirassu

    Department of Chemistry Chaitanya (Deemed to be University), Kishanpura, Hanumakonda Telangana India

    2 shared publications
  • Advaitha Vanaparthy

    Department of Chemistry Chaitanya (Deemed to be University), Kishanpura, Hanumakonda Telangana India

    1 shared publication
  • Annapurna Mamidala

    Department of Chemistry Chaitanya (Deemed to be University), Kishanpura Hanumakonda Telangana India

    1 shared publication

Latest Publications

  • Open Access

    Design and Synthesis of Fused 1,2,3-Triazolo-Pyrano-Quinazoline Using Copper(I) Catalysis: In silico Molecular Docking, in vitro Tyrosine Inhibition and ADMET Studies

    by Saidi Reddy Modugu, Gouthami Dasari, Satheesh Kumar Nukala, Ashok Kumar Bapuram, Raju Mannoori, Bandari Srinivas

    In this work, the synthesis of novel 1,2,3-triazolo-pyrano-quinazoline conjugates (6a-n) using well-known copper-catalyzed CuAAC and C-H arylation cascade reactions is carried out. The anticancer activity of these conjugates was evaluated against two human cancer cell lines, MCF-7 and HepG-2. The results showed that conjugate 6e exhibited more potent activity compared to the standard drug erlotinib, while compounds 6b, 6d and 6f displayed slightly lower activity compared to the standard drug. These four potent compounds (6b, 6d, 6e and 6f) were assessed in a cell survival assay employing the normal breast cell line MCF-10A. None of them showed significant cytotoxicity, with IC50 values larger than 98.20 µM. In vitro tyrosine kinase EGFR inhibitory of four potent compounds were evaluated and results indicate that compound 6e exhibited higher EGFR inhibitory activity compared to the standard drug erlotinib. On the other hand, compounds 6b and 6f displayed lower activity compared to both the standard drug and compound 6e. Furthermore, the molecular docking studies were also performed on four potent conjugates and the results showed that these conjugates had more EGFR-binding interactions as compared to the standard drug erlotinib. Moreover, the in silico pharmacokinetic outline of the potent conjugates 6b, 6d, 6e and 6f was estimated by using SWISS/ADME and pkCSM and all the four conjugates followed Lipinski rule of five, Ghose, Veber, Egan and Muegge rules without any deviation.

  • Open Access

    Synthesis of Indole-Thiazolidinedione-1,2,3-triazole Conjugates as Tubulin Polymerization Inhibitors and Some in silico Studies

    by Veeraboina Lingaswamy, Raja Shekhar Kondrapolu, Ashok Kumar Bapuram, Satheesh Kumar Nukala, Ravinder Manchal

    In this work, new hybrid compounds (7a-o) embedded with indole, thiazolidinedione and 1,2,3-triazole pharmacophores using Cu(I) catalyzed azide alkyne cycloaddition as key approach were synthesized and characterized. All these compounds were tested for their in vitro anticancer activity against three human cancer cell lines such as A549, MCF-7 and HeLa and nocodazole was used as reference drug. Compounds 7a, 7c, 7g, 7l and 7n have shown predominant activity than nocodazole towards three cell lines with IC50 values ranging from 0.3 to 1.37 µM. These five potent compounds were further screened for in vitro tubulin polymerization inhibition assay, where compounds 7c, 7g, 7l and 7n exhibited more inhibition than the standard drug combretastatin A4 (CA-4). In in silico molecular docking studies all these five compounds displayed remarkable binding energies with target protein α,β-tubulin (PDB ID: 1SA0). Further, results of in silico ADMET of the same five compounds revealed that they followed Lipinski rule, Veber rule, Egan rule and Muegge rules without any deviation and lipophilicity (Log Po/w) of the compounds was ranging from 2.80 to 4.06. Finally, compound 7n was characterized using density functional theory (DFT) with B3LYP/6–311++G (d,p) basis set.

  • Synthesis of Fused Isoxazoles of Iodoquinol as in vitro EGFR Aiming Anticancer Agents

    by Karthik Bokkala, Ashok Kumar Bapuram, Narasimha Swamy Thirukovela, Satheesh Kumar Nukala

    We have presented the synthesis of some new quinoline linked fused isoxazoles via copper (I) catalyzed azide alkyne cycloaddition (CuAAC) followed by intramolecular C−H arylation of isoxazole ring using PdCl 2 (PPh 3 ) 2 catalyst. All the synthesized compounds were investigated for anticancer activity against three human breast cancer cell lines such as MCF‐7, MDA‐MB‐468 and MDA‐MB‐231 using MTT assay and 5‐fluorouracil (5‐FU) was used as a standard drug. In this study, three compounds were exhibited greater activity than reference drug 5‐FU against three cell lines which further screened for in vitro tyrosine kinase EGFR inhibition and molecular docking studies by taking EGFR protein as the target. Finally, insilico pharmacokinetic profile of the same compounds was obtained using SWISSADME where two compounds following Lipinski, Ghose, Veber, Egan, and Muegge rules.


  • Ring‐B Modification of Combretastatin A‐4 to Generate Thiazolidine‐2,4‐dione‐1,2,3‐triazole Hybrids as Tubulin Polymerization Inhibitors

    by Advaitha Vanaparthy, Karthik Bokkala, Narasimha Swamy Thirukovela, Narsimha Sirassu, Ravinder Manchal, Bandari Srinivas, Satheesh Kumar Nukala

    In this work we have described the synthesis of thiazolidine‐2,4‐dione‐1,2,3‐triazole hybrids ( 7 a – n ) via ring‐B modification of Combretastatin A‐4 involving reactions namely Knoevenagel condensation, O‐propargylation and finally copper (I) catalyzed azide‐alkyne cycloaddition (CuAAC). They were tested for the in vitro anticancer activity against A549, MCF‐7 and HeLa cell lines using MTT assay where some compounds were exhibited more potency than the Nocodazole. In vitro tubulin polymerization inhibition assay for the same compounds revealed that they were more potent in inhibiting tubulin with IC 50 values ranging from 0.22 μM to 0.64 μM compared reference drug Combretastatin A‐4. Molecular docking studies of active compounds with α,β‐tubulin revealed that they compounds have more binding energies than that of combretastatin A‐4. Finally, in silico pharmacokinetic profile was achieved for the same compounds using SWISS/ADME and pkCSM, where some of them have followed Lipinski rule and Veber rule.


  • Synthesis of Quinoline‐Morpholine‐Coupled 1,2,3‐Triazole Hybrids as In vitro EGFR inhibitors

    by Annapurna Mamidala, Karthik Bokkala, Narasimha Swamy Thirukovela, Narsimha Sirassu, Srinivas Bandari, Satheesh Kumar Nukala

    Herein we described the synthesis of some new quinoline‐morpholine coupled 1,2,3‐triazole hybrids ( 6 a – n ) from 5‐chloroquinolin‐8‐ol using well known reactions like Mannich reaction, O‐propargylation, and finally copper (I) catalyzed azide‐alkyne cycloaddition (CuAAC). The structures of all newly synthesized hybrids were confirmed by 1 H–NMR, 13 C–NMR, and Mass spectra. All of them were screened for their in vitro cytotoxicity towards three human cancer cell lines including MCF‐7, A549 and HepG2 by MTT assay where four compounds ( 6 c , 6 j , 6 m and 6 n ) exhibited more potency than the reference erlotinib against all the three cell lines. In vitro tyrosine kinase EGFR inhibition assay for the same four compounds revealed that 6 m has triple inhibiting power with IC 50 value of 0.14 μM and 6 j has nearly double inhibiting power with IC 50 value of 0.22 μM compared to erlotinib. Molecular docking studies with EGFR have shown that all the above four compounds have more binding energies (−9.09 kcal/mol to −9.96 kcal/mol) than that of erlotinib (‐7.69 kcal/mol). Finally, in silico pharmacokinetic profile was achieved using SWISS/ADME and pkCSM, where all the four compounds followed Lipinski rule, Veber rule, Egan rule and Muegge rule and the lipophilicity (ClogP) was found to be ranging from 2.98 to 3.69.


  • Aldol Reactions

    by M. Periasamy, M. N. Reddy, N. S. Kumar

    Science of Synthesis is your online synthetic methodology tool for the most reliable chemical transformations available!